Article
Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Cancer research - 1 Mar 2011
Fischer Marcus, Yen Wan-Ching, Kapoun Ann M, Wang Min, O'Young Gilbert, Lewicki John, Gurney Austin, Hoey Timothy
Abstract excerpt
KRAS mutations are frequent in colorectal cancer (CRC) and are associated with clinical resistance to treatment with the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies. Delta-like 4 ligand (DLL4) is an important component of the Notch signaling pathway and mediates stem cell self-renewal and vascular development. DLL4 inhibition in colon tumor cells reduces tumor growth and stem cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.